15,154,606 Shares in Biogen Inc. $BIIB Purchased by Primecap Management Co. CA

Primecap Management Co. CA bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, HoldingsChannel reports. The fund bought 15,154,606 shares of the biotechnology company’s stock, valued at approximately $3,274,304,000. Biogen makes up about 1.9% of Primecap Management Co. CA’s investment portfolio, making the stock its 9th largest position. Primecap Management Co. CA owned 0.10% of Biogen as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Reflection Asset Management acquired a new stake in Biogen during the 4th quarter valued at approximately $25,000. Bell Investment Advisors Inc acquired a new stake in shares of Biogen in the second quarter worth $27,000. WFA of San Diego LLC purchased a new position in shares of Biogen during the second quarter worth $32,000. Root Financial Partners LLC lifted its position in Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. Finally, MV Capital Management Inc. acquired a new position in Biogen during the fourth quarter valued at $34,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Performance

NASDAQ BIIB opened at $220.77 on Wednesday. The stock has a market capitalization of $32.62 billion, a price-to-earnings ratio of 39.07, a PEG ratio of 6.80 and a beta of 0.17. The stock has a 50-day moving average of $206.42 and a 200 day moving average of $195.12. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Biogen Inc. has a twelve month low of $131.52 and a twelve month high of $222.85.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the company earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Analyst Ratings Changes

Several equities research analysts have commented on BIIB shares. Mizuho increased their price target on Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Barclays boosted their price objective on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Biogen in a report on Monday, July 13th. HC Wainwright boosted their price target on Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, TD Cowen upped their price objective on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $227.79.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.